A 65-year-old newly diagnosed diabetic with HbA1c 10%, hypertension, dyslipidaemia, osteoarthritis and BMI 35 refuses to adhere to diet a…

Frame the problem before naming a drug. This man has obesity-driven type 2 diabetes with a very high HbA1c (10%), hypertension, dyslipidaemia and osteoarthritis — a cluster that is essentially the metabolic syndrome with a mechanical complication. Two consequences follow. First, at 65 with a long life expectancy he is not in the "frail, relax the target" category; aim for an HbA1c around 7.0–7.5%. Second, his refusal of diet and exercise is not a reason to abandon lifestyle counselling but a reason to choose drugs that deliver weight loss and cardiovascular and renal protection independently of adherence — the pharmacological choice must do the work that lifestyle is not doing.

First-line: metformin, and start it at diagnosis. Metformin is first-line therapy in overweight diabetic patients. It is weight-neutral to weight-reducing, does not cause hypoglycaemia, and is inexpensive — decisive in Indian practice. Start 500 mg once daily with food and titrate slowly to limit gastrointestinal intolerance; use the extended-release preparation if needed. Check eGFR before starting and periodically: do not use metformin in renal insufficiency or heart failure, reduce the dose below an eGFR of 45 and stop below 30, and monitor vitamin B12 on long-term therapy.

An HbA1c of 10% will not be controlled by metformin alone — start combination therapy immediately. Metformin lowers HbA1c by about 1–1.5%, which leaves him well short of target. Current practice is that when HbA1c is more than 1.5–2% above target, dual therapy should be initiated from the outset rather than sequentially. If he were markedly symptomatic with polyuria, polydipsia and weight loss, or had glucose above 300 mg/dL or ketosis, the correct answer would be initial basal insulin to relieve glucotoxicity, with subsequent de-escalation to oral agents once glucose falls — but the question describes weight gain, not catabolism, so combination oral and injectable non-insulin therapy is appropriate.

Second agent: a GLP-1 receptor agonist — the best fit for this specific patient. Its advantages align exactly with his problem list: the largest HbA1c reduction of the non-insulin classes (about 1.0–1.5%), substantial weight loss (3–6 kg, more with semaglutide or tirzepatide), no intrinsic hypoglycaemia because insulin release is glucose-dependent, proven benefit in established atherosclerotic cardiovascular disease, and — critically here — weight loss is the single most effective disease-modifying intervention for knee osteoarthritis, so one drug addresses the diabetes, the obesity and the joint. Counsel about nausea, vomiting and anorexia, titrate slowly, and monitor for excessive weight loss and sarcopenia. Cost is the practical barrier in India.

Third agent, or an alternative second agent: an SGLT2 inhibitor. Add empagliflozin or dapagliflozin for the hypertension (a modest natriuretic blood-pressure reduction), for cardiovascular and renal protection irrespective of HbA1c, and for 2–3 kg of weight loss without hypoglycaemia. Generic empagliflozin and dapagliflozin are widely available and inexpensive in India, which makes this the pragmatic partner for metformin where a GLP-1 receptor agonist is unaffordable. Counsel on genital mycotic infection, perineal hygiene, volume depletion, and sick-day rules, and warn about euglycaemic ketoacidosis.

What to avoid, and the non-drug obligations you must still discharge. Avoid sulphonylureas — they cause hypoglycaemia and weight gain, both wrong for this man; avoid thiazolidinediones — do not use in heart failure, and they cause weight gain, fluid retention and fracture; use DPP-4 inhibitors only as a weight-neutral, well-tolerated fallback, remembering that they showed no cardiovascular benefit. Alongside the diabetes: treat the hypertension — the antihypertensive regimen of a diabetic should include an ACE inhibitor or ARB — prescribe a statin, since therapy of these risk factors may be of greater benefit than tight glucose control in older diabetics, and manage the osteoarthritis with paracetamol, topical NSAIDs, physiotherapy and quadriceps strengthening rather than systemic NSAIDs, which threaten his kidneys and blood pressure. Finally, his refusal is a communication problem, not a closed door: use motivational interviewing, negotiate one small, specific, achievable change, involve the family, and revisit it at every visit. Agent HbA1c effect Weight Why it fits — or does not Watch for Metformin ↓1.0–1.5% Neutral / ↓ First-line in the GI upset, B12 deficiency; overweight; cheap, no avoid if eGFR <30 or heart hypoglycaemia failure GLP-1 RA ↓1.0–1.5% ↓↓ 3–6 kg Best fit — diabetes + Nausea, anorexia, sarcopenia, obesity + knee OA + ASCVD gallstones, cost risk SGLT2 inhibitor ↓0.5–0.8% ↓ 2–3 kg BP lowering, cardiorenal Genital infection, volume protection, cheap generics depletion, euglycaemic DKA in India DPP-4 inhibitor ↓0.5–0.8% Neutral Fallback only — well Rare pancreatitis; do not tolerated but no CV benefit combine with GLP-1 RA Sulphonylurea ↓1.0–1.5% ↑ Avoid — hypoglycaemia and Glibenclamide is a Beers-weight gain criteria drug Pioglitazone ↓0.8–1.2% ↑↑ Avoid — oedema, heart Bladder cancer signal; failure, fracture worsens immobility Basal insulin Unlimited ↑ Only if catabolic, glucose Hypoglycaemia; de-escalate >300 mg/dL or ketosis once glucotoxicity resolves 65 years · HbA1c 10% · BMI 35 · HTN · dyslipidaemia · knee OA · refuses lifestyle change ↓ Symptomatic, catabolic, glucose >300 mg/dL or ketosis? → Yes = start basal insulin first, de-escalate later ↓ No Start dual therapy from the outset: Metformin + GLP-1 receptor agonist (weight, ASCVD, knee OA) ↓ if cost prohibits GLP-1 RA Metformin + SGLT2 inhibitor (BP, cardiorenal, cheap generic in India) ↓ if HbA1c still above target at 3 months Triple therapy: Metformin + GLP-1 RA + SGLT2 inhibitor · then basal insulin if needed ↓ In parallel, always ACE inhibitor or ARB · statin · paracetamol and topical NSAID with quadriceps strengthening for the knee · motivational interviewing at every visit LATEST UPDATE (2023–PRESENT) — 1 POINT

ADA Standards of Care 2026 — treat the comorbidity, not just the glucose, and treat the obesity as a disease. Glucose-lowering therapies are now recommended explicitly for heart, kidney and liver protection independent of HbA1c, and there is new guidance on individualised dosing of obesity medications in people with diabetes. For this patient with a BMI of 35, that reframes the question: obesity is a treatment target in its own right, and tirzepatide, a dual GIP/GLP-1 receptor agonist, delivers the greatest combined HbA1c and weight reduction of any non-insulin agent. Two further points make this directly examinable: the SELECT trial showed cardiovascular benefit from semaglutide in overweight and obese patients without diabetes, confirming that the benefit is not purely glycaemic; and ADA Section 12 highlights a GLP-1-associated reduction in amputation risk. The geriatric caveat to state alongside this: these agents cause loss of lean mass as well as fat, so in anyone over 65 you must ensure adequate protein intake and resistance exercise, and monitor for sarcopenia — which, incidentally, is the argument that finally persuades many patients to accept the exercise they had refused.